Understanding CJC-1295 Without DAC
CJC-1295 Without DAC, also referred to as Modified GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). This 29-amino acid peptide has been modified from the native GHRH sequence to enhance its stability and resistance to enzymatic degradation in laboratory conditions.
The “Without DAC” designation distinguishes it from the Drug Affinity Complex version, indicating this form does not include the lysine-linked maleimidopropionic acid modification designed for albumin binding. This distinction is important for researchers, as the pharmacokinetic profiles differ significantly in preclinical models.
Molecular Modifications & Stability
Amino Acid Substitutions
CJC-1295 Without DAC incorporates four amino acid substitutions at positions 2, 8, 15, and 27 compared to native GHRH(1-29). These modifications were designed to:
- Increase resistance to dipeptidyl peptidase IV (DPP-IV) cleavage
- Enhance overall peptide stability in solution
- Maintain receptor binding affinity
- Improve the compound’s utility as a research tool
Stability Considerations
In laboratory stability studies, CJC-1295 Without DAC has demonstrated improved resistance to enzymatic degradation compared to native GHRH(1-29). This enhanced stability makes it more practical for research protocols that require consistent compound integrity over experimental timeframes.
GHRH Receptor Interaction
Research has characterized CJC-1295 Without DAC’s interaction with the GHRH receptor (GHRH-R). In-vitro receptor binding assays have demonstrated that the modified sequence maintains binding affinity while offering improved stability. This receptor specificity differentiates it from growth hormone secretagogues like Ipamorelin, which act through the GHS-R1a receptor.
Research Applications
Pituitary Cell Models
CJC-1295 Without DAC has been utilized in pituitary somatotroph cell models to study GHRH-mediated signaling cascades. These in-vitro systems allow researchers to examine receptor activation, cAMP generation, and downstream signaling events.
Combined Secretagogue Research
A major research application involves combining CJC-1295 Without DAC with GHS receptor agonists. The CJC-1295/Ipamorelin 2X Blend is one of the most popular research combinations, as it allows simultaneous investigation of both GHRH and GHS pathways.
Pulse vs. Sustained Stimulation Studies
The absence of the DAC modification means CJC-1295 Without DAC has a shorter activity window in research models compared to the DAC version (CJC-1295 With DAC). This makes it valuable for studying pulsatile stimulation patterns versus sustained activation in laboratory models.
Comparison: With DAC vs. Without DAC
- CJC-1295 Without DAC: Shorter activity profile, suited for pulsatile research models, no albumin binding
- CJC-1295 With DAC: Extended activity profile due to albumin binding, suited for sustained stimulation studies
Both forms have distinct research applications, and the choice depends on the experimental objectives.
Storage & Handling
- Store lyophilized at -20°C, protected from light
- Reconstitute with bacteriostatic water
- Reconstituted solutions should be refrigerated at 2-8°C
- Avoid repeated freeze-thaw cycles
Conclusion
CJC-1295 Without DAC remains a cornerstone research peptide for GHRH pathway investigation. Its enhanced stability, maintained receptor affinity, and compatibility with multi-peptide research protocols make it an essential tool for growth hormone research. Molecular Peptides provides CJC-1295 Without DAC (10mg) with comprehensive analytical documentation.